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Abstract
Background. The Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) working
group aims to provide guidance on the use of PROs in brain tumor patients. PRO measures should be of high
quality, both in terms of relevance and other measurement properties. This systematic review aimed to identify
PRO measures that have been used in brain tumor studies to date.
Methods. A systematic literature search for articles published up to June 25, 2020 was conducted in several electronic databases. Pre-specified inclusion criteria were used to identify studies using PRO measures assessing
symptoms, (instrumental) activities of daily living [(I)ADL] or health-related quality of life (HRQoL) in adult patients
with glioma, meningioma, primary central nervous system lymphoma, or brain metastasis.
Results. A total of 215 different PRO measures were identified in 571 published and 194 unpublished studies.
The identified PRO measures include brain tumor-specific, cancer-specific, and generic instruments, as well as

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European
Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Downloaded from https://academic.oup.com/nop/article/8/4/417/6134357 by Henry Ford Hospital user on 30 September 2021

Systematic review on the use of patient-reported
outcome measures in brain tumor studies: part of the
Response Assessment in Neuro-Oncology PatientReported Outcome (RANO-PRO) initiative

418

Dirven et al. Use of PRO measures in brain tumor studies

instruments designed for other indications or multi- or single-item study-specific questionnaires. The most
frequently used instruments were the EORTC QLQ-C30 and QLQ-BN20 (n = 286 and n = 247), and the FACT-Br
(n = 167), however, the majority of the instruments were used only once or twice (150/215).
Conclusion. Many different PRO measures assessing symptoms, (I)ADL or HRQoL have been used in brain
tumor studies to date. Future research should clarify whether these instruments or their scales/items exhibit
good content validity and other measurement properties for use in brain tumor patients.

activities of daily living | brain tumor | health-related quality of life | patient-reported
outcome | symptoms

Traditional outcomes to assess the impact of a treatment in
adult brain tumor patients are progression-free or overall
survival and radiological response on imaging. With an
increasing focus on patient-centered care and the need for
therapies to show improvement in symptom burden, patient function, and health-related quality of life (HRQoL),
the emphasis on the use of patient-reported outcome
(PRO) measures is growing.1–3 PRO measures reflect the
patient’s health status based on the patient’s self-report,
without amendment or interpretation by a clinician or anyone else.4,5 PRO measures are important to quantify the
symptom burden, patient function, or overall HRQoL, but
might also cover topics such as needs and coping.
Findings from PROs together with outcomes such as survival and tumor response are essential to inform the research community and policy makers on the net clinical
benefit of a tumor-directed treatment, and to assist physicians and patients in clinical decision-making. It is therefore important that PRO measures are of high quality in
terms of relevance (content validity) and other measurement properties, to create high-quality evidence.4 The content that is considered relevant depends on the setting
and the research question. Regulators aim to accurately
capture the patient perspective during clinical trials to inform the regulatory decision-making process.6 Concepts
of interest to the regulators are disease symptoms, symptomatic adverse events, and physical function.3,7 When
considering patient-centered assessments in evaluation
of therapeutic trials, clinical investigators may be interested in concepts that are a surrogate to primary survival
or response outcomes such as disease-related symptoms
or functions that reflect therapeutic tolerability, but also
aspects such as activities in daily life and participation in
society, as described by the World Health Organization
International Classification of Functioning, Disability and
Health (WHO ICF).8 In the WHO ICF framework, disability
and functioning are seen as an interaction between the
disease and contextual factors, such as environmental factors (eg, social structures) and personal factors (eg, coping
styles and character). Although it is understandable from
the regulator’s point of view to only assess those outcomes
that directly reflect a treatment effect, for researchers
and clinicians it may be important to capture information on the entire spectrum of the patients’ functioning
and well-being, including contextual factors. This may be

particularly useful in clinical practice, where the obtained
information could be tailored to the specific needs of the
individual patient. This is also emphasized by results of the
Jumpstarting Brain Tumor Drug Development (JSBTDD)
Coalition survey in glioma patients, showing that patients
particularly would like treatments to result in maintenance
of physical functioning (including walking), cognitive abilities, as well as reduction or relief of symptoms including
pain, weakness, seizures, aphasia, alterations and mood,
and perceived cognitive symptoms.9
As advocated by the FDA, developing appropriate instruments to measure clinical outcome assessments
(COAs) in neuro-oncology, including PROs, should include
identifying areas requiring new tools and reviewing existing tools that may be suitable or adapted for use in clinical trials.7 The JSBTDD initiative identified priority signs
and symptoms, reviewed properties of existing COAs and
considerations for trial design including COAs, and serves
as a starting point for further guidelines on outcome assessment in neuro-oncology.9 PRO measures being used
in brain tumor studies may not have been developed and/
or validated for use in this condition, and with the development of new treatment strategies associated with different
toxicity profiles, currently available PRO measures may
also no longer be sufficiently comprehensive to address
toxicities associated with new therapeutic approaches. In
addition, it is also important that the instruments exhibit
good other measurement properties, such as sensitivity to
known group comparisons, reliability, and responsiveness.
The Response Assessment in Neuro-Oncology PatientReported Outcome (RANO-PRO) initiative builds on the
JSBTDD initiative and aims to provide guidance on the
use of PRO measures, with respect to their measurement
properties and content, in research studies and daily
practice for adult brain tumor patients.10 In addition,
suggestions for the revision of existing PRO measures
and the development of new PRO measures or measurement strategies for use in neuro-oncology will be
provided if warranted. For this multistep process, PRO
measures that have been used in studies of brain tumor
patients first need to be identified and subsequently reviewed for content validity and other psychometric properties. This systematic review aimed to identify studies
in which a PRO measure was used to assess symptoms
and signs, (instrumental) activities of daily living [(I)ADL]
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Methods
An extensive literature search for articles published up to
June 25, 2020 (there was no specific start date) was conducted in the following electronic databases: PubMed/
Medline, Embase, Web of Science, Cochrane Library,
PsycINFO, Emcare, and Academic Search Premier. The
search string consisted of a combination of terms related to “PRO measures” and “brain tumors” (see
Supplementary File 1 for the complete search string in
PubMed). The search string was adapted for the other
electronic databases. In addition, clinicaltrials.gov was
consulted for additional eligible studies initiated in the
last decade but may not yet have been published; ie, with
a study start between January 1, 2010 and June 25, 2020
(see Supplementary File 2 for the complete search string).
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines were followed for
screening procedures.11

Selection Criteria
All retrieved titles and abstracts were independently
screened by two reviewers (M.E.V. and L.D.). Articles had to
report the use of a PRO measure to assess aspect(s) of functioning, including symptoms and signs, (I)ADL or HRQoL in
patients with glioma, meningioma, PCNSL, or brain metastases. All study designs (eg, randomized controlled trials
and observational cohort studies) were deemed eligible. To
align with the work of the RANO-PRO, (1) ≥75% of the study
population had to concern patients with glioma, meningioma, PCNSL, and/or metastatic brain tumor. Other inclusion criteria were (2) at least one PRO measure is used and
specified, (3) the PRO measure used addresses symptoms
and signs, (I)ADL or HRQoL, (4) adult patients (≥18 years),
(5) a sample of ≥10 patients, (6) original articles (eg, no systematic review articles, conference papers, or study protocols), (7) articles in English, (8) full-text availability, and (9)
peer-reviewed articles. The first five inclusion criteria were
also used for the assessment of additional eligible studies
on clinicaltrials.gov. After screening titles and abstracts,
full-texts of potentially relevant articles were examined for
eligibility by the same two reviewers, applying the same
criteria. Disagreements between the reviewers were discussed and resolved by consensus.

Data Extraction
The following data were extracted from the eligible articles and studies on clinicaltrials.gov to gain insight into

Results
The literature search yielded 5715 unique records.
Screening of titles and abstracts resulted in 997 potentially
eligible articles. These articles were read full-text, and 621
met the inclusion criteria. Based on the study number and
names reported in the 621 articles, 571 different studies
were identified. The search on clinicaltrials.gov yielded 543
unique studies, which were screened for eligibility. A total
of 210 studies met the inclusion criteria, of which 16 were
already reported in one of the identified articles, resulting
in 194 unpublished studies. In total, 765 unique published
and unpublished studies were identified that used a PRO
measure to report on symptoms and signs, (I)ADL and/or
HRQoL in brain tumor patients. The flow diagram of the selection processes is shown in Supplementary Figure 1. The
reference list of all articles and NCT (National Clinical Trial)
numbers (ClinicalTrials.gov registry number) are shown in
Supplementary Files 3 and 4.
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Search Strategy

the type of brain tumor studies that used PRO measures: tumor type, (estimated) sample size, study design,
study ID number (if available), PRO measure used and
whether the PRO measure was used as primary or secondary endpoint, and for studies on clinicaltrials.gov
only the study status. The actual outcomes (eg, number
and severity of specific symptoms) as assessed with the
PRO measures were not reported, as this review was focused on identifying the instruments only. In addition,
information about the PRO measures was retrieved from
the articles, cited publications, or web resources to gain
insight into the intended use and structure of the identified PRO measures, including the number of items,
population of intended use, and subscales (reflecting
the concepts of interest). Information about the population of intended use was based on our interpretation
if official information was not available. Identified PRO
measures were excluded from further analyses if they
(1) did not assess symptoms and signs, (I)ADL or HRQoL
(eg, coping styles or satisfaction with care), (2) were
not intended to be used as PRO measure (eg, Lawton
Instrumental Activities of Daily Living Scale or Hamilton
Depression Rating Scale, which are completed by observers such as proxies), (3) were not available in English,
or (4) could not be retrieved or otherwise judged for eligibility. If at least one subscale in a PRO measure was
relevant, the PRO measure was considered eligible.
Some PRO measures have been revised over the years,
and therefore, different versions were identified. These
versions may have (slightly) different items or response
scales. For this review, the different revised questionnaire versions were not considered as separate instruments. The original versions and the short form versions
of questionnaires were reported as separate instruments
(eg, Medical Outcomes Study 36-item Short Form Health
Survey [SF-36] and Medical Outcomes Study 12-item
Short Form Health Survey [SF-12]). Data extraction was
performed by one researcher (M.E.V.), however, ambiguities were discussed and agreed upon with another researcher (L.D.).
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or HRQoL in patients with glioma, meningioma, primary
central nervous system lymphoma (PCNSL), or brain metastases. The results serve as a foundation for further
evaluation.
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Main Characteristics of Included Studies

Identified PRO Measures

Characteristics

Published Studies
(n = 571)

Unpublished
Studies (n = 194)

n

%

n

%

Year of publication
1990-2000

35

6

-

2001-2010

125

22

-

2011-2020

411

72

-

Type of brain tumor (multiple tumor types possible)
Glioma

401

70

106

Meningioma

116

20

7

PCNSL

31

5

6

3

Brain metastases

152

27

78

40

91

16

3

2

  RCT

106

19

78

40

  Non-RCT

13

2

20

10

  Single arm

92

16

81

42

  Cross-sectional

141

25

0

0

  Cohort

192

34

15

8

  Case-control

20

3

0

0

7

1

0

0
3

 Unspecified/other
brain tumors

55
4

Study design
Interventional

In total, 215 unique PRO measures that met our inclusion criteria were identified (Figure 1). These were both
multi-item and single-item questionnaires. Information
about the top 20 instruments (those that were used in at
least 10 studies), including the number of items, population of intended use, and subscales are displayed in Table
2 (see Supplementary Table 1 for an overview of all PRO
measures). The population of intended use was classified
as brain tumor-specific, cancer-specific, central nervous
system (CNS) disorders, and generic or for other indications. The concepts of interest were mixed in the studies,
focusing on one aspect only (eg, symptom(s)) or covering
multiple aspects (eg, symptoms and (I)ADL).
The 215 identified PRO measures represent 40 (19%)
brain tumor-specific instruments, 37 (17%) cancer-specific
instruments, 13 (6%) CNS disorder instruments, 79 (37%)
generic instruments, and 46 (21%) instruments intended
for other indications.

Frequency of Use of PRO Measures
Although many different PRO measures were identified,
only a few have been frequently used in the identified
brain tumor studies. In both the published and unpublished studies, a mean of two PRO measures assessing
symptoms and signs, (I)ADL and/or HRQoL were included.
Of the 215 identified PRO measures, 20 instruments (9%)
were used in 10 studies or more. The top 10 most frequently used instruments were used in 24-286 studies, and
include brain tumor-specific instruments (n = 3) as well as
cancer-specific instruments (n = 2), generic instruments
(n = 4), and instruments for other indications (n = 1).
The most frequently used instrument is the European
Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
in n = 286 studies, often combined with the European
Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire - Brain Cancer 20 (EORTC QLQ-BN20)
module (used in n = 247 studies), but also used as
standalone questionnaires. Other PRO measures in the top

Observational

Other

Endpoint of PRO measure
Primary

182

32

6

Secondary

257

45

173

Co-primary

107

19

6

3

25

4

9

5

1

 Primary and
secondary

89

Follow-up of PRO measure
Cross-sectional

208

36

2

Longitudinal

363

64

192

99

-

114

59

Study status
Recruiting

-

11

6

 Active, not
recruiting

Not yet recruiting

-

30

15

Completed

-

28

14

 Enrolling by
invitation

-

0

0

Suspended

-

1

1

Terminated

-

10

5

PCNSL, primary central nervous system lymphoma; PRO, patientreported outcome; RCT, randomized controlled trial.
  

10 of frequently used instruments measuring HRQoL are
the brain tumor-specific Functional Assessment of Cancer
Therapy-Brain (FACT-Br; n = 167), the generic EuroQoL
five-dimensional instruments (EQ-5D; n = 60), the generic
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The main characteristics of the included published (n = 571)
and unpublished (n = 194) studies are presented in Table 1.
The majority of the published (n = 401, 70%) and unpublished (n = 106, 55%) studies included glioma patients.
Populations of mixed brain tumor types were included in
178 of the published studies (31%) and 10 of the unpublished studies (5%). The median sample size of brain tumor
patients was 63 (IQR = 33-116) in the published studies and
60 (IQR = 37-136) in the unpublished studies.
The majority of the published studies were observational studies (n = 353, 62%) and included PRO measures
most frequently as primary or co-primary outcome measures (n = 314). On the other hand, the unpublished studies
were mostly interventional studies (n = 179, 92%) and included PRO measures almost always as secondary outcome measure (n = 173).

  

Table 1. Main Characteristics of the Unique Published (Described in
Articles) and Unpublished (Registered on clinicaltrials.gov) Studies

Dirven et al. Use of PRO measures in brain tumor studies

Neuro-Oncology
Practice

Possible eligible PRO
measures identified
(n = 325)
Articles (n = 256)
Clinicaltrials.gov (n = 69)

Unique instruments
assessed
for eligibility
(n = 272)

Instruments excluded,
with reasons
(n = 57)
PRO covers other topic (n = 34)
Not available in english (n = 7)

Instruments included in
systematic review
(n = 215)

Not intended as PRO (n = 14)
Not available for evaluation (n = 2)

Figure 1. Flow diagram (PRISMA) of the selection process of PRO measures. Abbreviations: PRISMA, Preferred Reporting Items for Systematic
Reviews and Meta-Analyses; PRO, patient-reported outcome.
  

Medical Outcomes Study SF-36 (n = 52), the cancer-specific
NCCN (National Comprehensive Cancer Network) distress
thermometer and problem list (DT + PL; n = 30), and the
Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F; n = 24) questionnaire. Further, the MD Anderson
Symptom Inventory-Brain Tumor (MDASI-BT) was frequently used to assess symptom burden and (I)ADL specific to brain tumor patients (n = 49). Lastly, the generic
Hospital Anxiety and Depression Scale (HADS; n = 70) was
frequently used to assess symptoms of anxiety and depression, and the generic Beck Depression Inventory (BDI/
BDI-II; n = 47) to assess symptoms of depression only.
An important finding was that the majority of the identified PRO measures were only used once (121/215; 56%) or
twice (29/215; 13%). The large majority (84%) of these instruments was used in observational studies and may reflect the evaluation of constructs in this population using
multi- or single-item scales previously developed for other
populations related to universal nature of the study outcome (ie, fatigue or depression), psychometric evaluation
of these scales, or scale development.

Use of PRO Measures per Tumor Type and
Study Type
To assess how often the identified PRO measures were
used in the different tumor types, we evaluated the 20 most
frequently used PRO measures. Figure 2 shows that the
majority of instruments were used in all brain tumor types.
In addition, Figure 3 shows that the type of instrument is
somewhat related to the study design. The most commonly
used brain tumor-specific instruments (EORTC QLQ-BN20,

FACT-Br, and MDASI-BT) were most often used in interventional studies, while generic PRO measures such as HADS,
SF-36, EQ-5D, and BDI were most often used in observational studies.

Discussion
In this systematic review, we have identified 215 different
multi-item or single-item PRO measures that have been
used in brain tumor studies to assess symptoms and signs,
(I)ADL or HRQoL. The majority of the instruments (70%)
were only used in one or two studies. The EORTC QLQ-C30,
often used in conjunction with the EORTC QLQ-BN20, and
FACT-Br were the most commonly used instruments in
both interventional and observational studies. Of note, in
European clinical trials, the EORTC instruments are more
commonly used, whereas the FACT instruments are more
often used in the United States. The identified PRO measures not only include instruments specifically designed for
brain tumor patients, but also cancer-specific instruments,
generic instruments, and instruments designed for other
indications.
Although certain instruments were often used in brain
tumor studies, they are not all designed and/or validated
for use in (specific types of) brain tumor patients. For example, the EORTC QLQ-BN20 was developed for and validated in glioma patients, but is also frequently used in other
types of brain tumor patients. Whether this questionnaire
exhibits good content validity for these other types of patients remains to be investigated. A small study in WHO
grade I meningioma did show that patients considered
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Eligibility

Identification

  

Included

421

  

1
5

19
15

European Organisation for
Research and Treatment of Cancer
Quality of Life Questionnaire Brain Cancer 20(+2)

Functional Assessment of Cancer
Therapy-Brain

The Hospital Anxiety and
Depression Scale

Short Form 36 Health Survey/
RAND-36/Medical Outcomes
Study

MD Anderson Symptom
Inventory Brain Tumor

Beck Depression Inventory (-II)

EuroQoL 5 dimensions (3 or 5
levels)

NCCN Distress Thermometer (and
Problem List)

Functional Assessment of
Chronic Illness Therapy-Fatigue

State-Trait Anxiety Inventory
Form Y

European Organisation for
Research and Treatment of Cancer
Quality of Life Questionnaire Core 15 - Palliative Care

Medical Outcomes Study
Cognitive Functioning Scale

Brief Fatigue Inventory

Functional Assessment of Cancer
Therapy-Cognitive Function

EORTC
QLQBN20(+2)a

FACT-Br

HADS

SF-36

MDASI-BT

BDI(-II)

EQ-5D

DT(+PL)

FACIT-F

STAI-Y

EORTC
QLQ-C15PAL

MOS CFS

BFI

FACT-cog

9

Cancerspecific

Cancerspecific

Generic

Cancerspecific

Generic

Other
indications

Cancerspecific

Generic

Generic

Brain
tumorspecific

Generic

Generic

Brain
tumorspecific

Brain
tumorspecific

Cancerspecific

Population of
Intended
Use

Interventional;
observational

6 factors (affective, cognitive, neurologic, constitutional, gastrointestinal, and interference)

28

1 (disease-specific concerns)

13

37

9

6

15

40

Interventional;
observational

6 (overall distress; spiritual/religious concerns; practical-;
family-; emotional-; physical problems)

1(+39)

Interventional;
observational
Interventional;
observational

2 (severity of fatigue; impact on daily function)
4 (perceived cognitive impairments; comments from others;
perceived cognitive abilities; impact on QoL)

Interventional;
observational

Interventional;
observational
10 (GHS; physical functioning; emotional functioning; fatigue;
nausea/vomiting; pain; dyspnea; insomnia; appetite loss and
constipation)
1 (cognitive function)

Interventional;
observational

2 (trait anxiety; state anxiety)

Interventional;
observational

Interventional;
observational

5 (mobility; self-care; usual activities; pain/discomfort; anxiety/
depression)

6

BDI: 3 (negative attitude toward self; performance impairment; Interventional;
somatic symptoms); BDI-II: 2 (affective; somatic)
observational

Interventional;
observational

8 (physical functioning; physical role; pain; general health; vitality; social function; emotional role; mental health)

36

21

Interventional;
observational

2 (anxiety symptoms; depression symptoms)

14

Interventional;
observational

5 (physical-; social/family-; emotional-; functional well-being;
disease-specific concerns)

50

Interventional;
observational

5 functional scales (physical; role; emotional; cognitive; social); 3 symptom scales (fatigue; nausea and vomiting; pain);
7 single items (dyspnea; insomnia; appetite loss, constipation;
diarrhea; financial difficulties) and GHS/QoL scale

4 (future uncertainty; visual disorder; motor dysfunction; com- Interventional;
munication deficit); 7 single items (headache; seizures; drowsi- observational
ness; hair loss; itchy skin; weakness of legs; bladder control)

Study Type in
Which Used

Subscales

20(+2)

30(+3)

# of
Items
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3

7

6

5

19

15

2

24

9

28

36

38

24

5

47

25

8

46

62

121

83

100

186

European Organisation for
Research and Treatment of Cancer
Quality of Life Questionnaire Core 30(+3)

EORTC
QLQC30(+3)
164

# Used in
Unpublished
Studies

# Used in
Studies
Published

Full Name

Characteristics of the 20 Most Frequently Identified Eligible PRO Measures

Abbreviation

Table 2.
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aOut

10
Spitzer Quality of Life Index
SQLI

10
Patient Weighted Quality of Life
in Epilepsy
QOLIE-31-P

of the 247 times, the EORTC QLQ-BN20 was used in published and unpublished studies, 216 times (87%) this was in conjunction with the EORTC QLQ-C30.

Interventional;
observational
5 (activity; daily living; health; support; outlook)
5
Cancerspecific

Interventional;
observational
7 (emotional well-being; social function; energy/fatigue; cognitive functioning; seizure worry; medication effects; overall
QoL) and health status
39
Other
indications

Interventional;
observational
1 (anxiety symptoms)
21
Generic
4
Beck Anxiety Inventory
BAI

6

Interventional;
observational
1 (depressive symptoms)
20
Other
indications
1
Zung Self-Rating Depression
Scale
ZSDS

10

Interventional;
observational
4 (physical-; social/family-; emotional-; functional well-being)
Functional Assessment of Cancer
Therapy-General
FACT-G

9

2

Cancerspecific

27

Study Type in
Which Used
# of
Items
Population of
Intended
Use
# Used in
Unpublished
Studies
# Used in
Studies
Published
Full Name
Abbreviation

Continued
  

Table 2.
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only 35% of the items of the EORTC QLQ-BN20 as relevant, while health care professionals considered all items
as relevant.12 In addition, many cancer-specific instruments and generic instruments have not been validated in
brain tumor patients, nor have instruments designed for
other indications. Also, it may be possible that the questionnaires that have been used only once or twice are actually very relevant for brain tumor patients. Therefore,
the content validity of the identified PRO measures, regardless of frequency of use in the various brain tumor
populations, warrants clarification and will be further
investigated as part of the RANO-PRO working plan. To
this end, the content validity of scales/items in the available PRO measures used in brain tumor studies will be
established by means of an international survey among
patients, their caregivers, and health care professionals
in the field of neuro-oncology. Participants will be asked
to identify those aspects that are most relevant to brain
tumor patients. Besides good content validity, future research should also clarify if the identified PRO measures,
or separate multi- or single-item scales, exhibit other good
measurement properties, such as reliability and responsiveness. These steps will identify those PRO measures or
scales that measure relevant aspects, but still need to be
optimized in terms of other measurement properties.
Given new developments in the treatment for brain
tumor patients, with distinct toxicity profiles, and the changing needs of patients during the disease course, a new
approach of measuring PROs is required. The current static
questionnaires, consisting of a fixed set of items, may
not meet the current demands of the regulators and academic researchers. A more flexible approach, in which a
standard set of items could be complemented with validated scales, could be a solution. This means that only
those scale(s) should be selected that are relevant to a
specific setting or research objective, which may possibly
also reduce the response burden for patients as only those
items are administered that are relevant for that situation.
Item libraries, which are large databases with multi-item
and single-item scales, could be used to create short item
lists that can be added to a core set of questions.13–15 This
allows to measure adverse effects that are specific for a
certain treatment, which may have been missed when
using static questionnaires in which these are not covered.
A difficulty with this approach is that many different (but
overlapping) questionnaires will arise, hampering comparability between studies. The Fast Track COA Group, including representatives of RANO, the RANO-PRO working
group, regulators, and patient representatives, recently
established a core set of symptom and functional constructs that should at least be included in all clinical trials
for high-grade glioma patients, enhancing comparability.16
These symptoms include pain, difficulty communicating,
perceived cognition, seizures, and symptomatic adverse
events (ie, depending on the treatment under investigation), and the functions include physical functioning and
role and social functioning. The next step is to select items/
scales from existing instruments that are suitable to assess
these concepts, particularly in terms of content validity.
This systematic review has some limitations. Although
a comprehensive search strategy was used, it is possible that relevant articles and PRO measures have been
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3
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4
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4
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8
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4

Other BT
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Figure 2. Percentage and number of times the 20 most frequently used PRO measures have been used in different types of brain tumor.
Abbreviation: BM, brain metastases; BT, brain tumor; PCNSL, primary central nervous system lymphoma; PRO, patient-reported outcome.
  

  

Interventional

Observational

100%
2

70%
56

60%

8
30

36

2

6

33

6

12
23

6

6

6

4

4

4

SQLI

15

QOLIE-31-P

90 86
80%
67

BAI

90%

8

16

50%

5

7

3
FACT-G

BFI

FACT-Cog
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FACIT-F

4
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7
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FACT-Br

14
QLQ-C30(+3)

0%

9

27

EQ-5D

10%

16

16

BDI(–11)

96

20%

16

MOS CFS

32

MDASI-BT

30%

11 10
192157

SF-36

40%

Figure 3. Percentage and number of times the 20 most frequently used PRO measures have been used in observational and interventional
studies. Abbreviation: PRO, patient-reported outcome.
  

missed due to the search strategy and selection criteria
that were applied. For example, if it was unclear which
tumor types were evaluated, the study was excluded from
further analyses. Also, it may be possible that there are

existing questionnaires that are relevant for brain tumor
patients, which have not been identified in this review
as we only focused on studies in brain tumor patients.
Another limitation is that there may be articles included
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describing the same study or dataset. Numbers or names
for studies or datasets are not always reported in articles,
which makes it difficult, if not impossible, to trace the use
of the same study or dataset. Furthermore, the classification of PRO measures in terms of population of intended
use (brain tumor-specific, cancer-specific, CNS disorders,
and generic or other indications) was suboptimal, as the
classification process is partly based on the judgment of
the reviewers, as not all information could be extracted
from the literature. Lastly, although we evaluated in
which tumor types the instruments were used, based on
the currently available data we cannot recommend which
instrument would be most suitable for each tumor type.
This also applied for evaluating specific treatments. First,
more information on the content validity and other psychometric properties is warranted.
In conclusion, 215 multi and single-item PRO measures
have been used in adult brain tumor studies to assess
symptoms and signs, (I)ADL and HRQoL. The majority of
these instruments are only used in one or two studies,
while few are frequently being used. Future research
should clarify whether the identified instruments or scales
exhibit good content validity and other measurement
properties for use in brain tumor patients.

425

